to improve the collection and publication of data on chemotherapy activity, outcomes and costs, the chemotherapy dataset will be introduced

Similar documents
Cancer Outcomes and Services Dataset: Implications for clinical teams

Clinical Commissioning Policy: Chemotherapy Algorithms for Adults and Children. January 2013 Reference: NHS England XXX/X/X.

Future Direction for Cancer Registries

Commissioning Chemotherapy Services Conference. Issues of consent in systemic therapy

Cancer Outcomes and Services Dataset. What is COSD? Skin Cancers Workshop October 2012

Progress in improving cancer services and outcomes in England. Report. Department of Health, NHS England and Public Health England

Informatics in the new NHS : PHE and NCIN 9 months on. Nicky Coombes National Cancer Intelligence Network

The National Cancer Dataset Initiative ddd CTYA SSCRG. Di Riley Associate Director for Clinical Outcomes

National Cancer Patient Experience Survey Results. Milton Keynes University Hospital NHS Foundation Trust. Published July 2016

Haemato-oncology Clinical Forum. 20 th June 2013

Type Days HRG Procurement 1 Cost and Volume Delivery 1 Day case. Weekly for 30 weeks. 1-14inc Capecitabine 1250mg/m² twice daily

OPCS Classification of Interventions and Procedures Version 4.6 (April 2011)

National Cancer Patient Experience Survey Results. University Hospitals of Leicester NHS Trust. Published July 2016

National Cancer Patient Experience Survey Results. East Kent Hospitals University NHS Foundation Trust. Published July 2016

Head and Neck Cancers Data Quality Report Radiotherapy and Chemotherapy Data

Understanding lymphoma: the importance of patient data

National Cancer Intelligence Network Routes to Diagnosis:Investigation of melanoma unknowns

What do we know about GBM Patient pathways in England?

Cancer and Data in the New NHS May Di Riley, Director Clinical Outcomes

National Cancer Peer Review Programme

NATIONAL BOWEL CANCER AUDIT The feasibility of reporting Patient Reported Outcome Measures as part of a national colorectal cancer audit

Waiting Times for Suspected and Diagnosed Cancer Patients

Rare Urological Cancers Urological Cancers SSCRG

Acute Oncology & Chemotherapy Clinical Network Group (CNG)

GOVERNING BODY REPORT

Connecting Cancer Data to Clinical Outcomes Intelligence

NHS RightCare Frailty Pathway An optimal frailty system

Breast Screening Data Stephen Scott Head of Informatics LCA

Routes to diagnosis 2015 update: multiple myeloma

Adult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference

NCIN Conference Feedback 2015

An Integrated National Strategy for Breast Cancer Audit. Martin Lee Gill Lawrence

National Optimal Lung Cancer Pathways. Dr Sadia Anwar Nottingham University Hospitals NHS Trust Clinical Lead for Lung Cancer

West Yorkshire Oral Health Needs Assessment 2015 (Draft)

Commissioning Cancer Services. Andy McMeeking RCGP/NCIN Primary Care Workshop, 13 th February 2013

SCHEDULE 2 THE SERVICES. A. Service Specifications

Cancer and Data in the New NHS May Di Riley, Director Clinical Outcomes

National Cancer Peer Review Sarcoma. Julia Hill Acting Deputy National Co-ordinator

Using Cancer Registration and MDT Data to Provide Information on Recurrent and Metastatic Breast Cancer

Top Regimens by Diagnostic Group. April July 2012

NHS Information Standards Board

Reference No: SG 23/13

Routes to diagnosis 2015 update: liver cancer (excluding intrahepatic bile duct)

REPORT TO CLINICAL COMMISSIONING GROUP

WORKING DOCUMENT Version 5 DRAFT LOCAL ENHANCED SERVICE SPECIFICATION Palliative Care

NHS Diabetes Programme

Apples and pears? A comparison of two sources of national lung cancer audit data in England

National Cancer Intelligence Network short report

WHERE NEXT FOR CANCER SERVICES IN WALES? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE

Activity Report March 2013 February 2014

Enhanced CPD Programme Module 1. Introducing Starting Well

NHS England (West Yorkshire) Dental Commissioning Update 2015/16

National Breast Cancer Audit next steps. Martin Lee

STATISTICAL PRESS NOTICE NHS REFERRAL TO TREATMENT (RTT) WAITING TIMES DATA JANUARY 2013

United Kingdom and Ireland Association of Cancer Registries (UKIACR) Performance Indicators 2017 report Published XX June 2017

HC 568 SesSIon november Department of Health. Delivering the Cancer Reform Strategy

Reducing the Door to Needle Time for Antibiotics in Suspected Neutropenic Sepsis using a Dedicated Clinical Pathway

Routes to diagnosis 2015 update: mesothelioma

30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study

Putting NICE guidance into practice

South Belfast Integrated Care Partnership. Transforming Delivery of Diabetes Care 2014

Developing Key Messages on Cancer for Commissioners

Present: Name: Initials

National Cancer Intelligence Network Short Report

LCA Lung Clinical Forum. 21 st October 2014

South Norfolk CCG Dementia Strategy and Action Plan Dr Tony Palframan, SNCCG Governing Body Member

FINANCE COMMITTEE DEMOGRAPHIC CHANGE AND AGEING POPULATION INQUIRY SUBMISSION FROM NATIONAL OSTEOPOROSIS SOCIETY

COLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer

What is Acute Oncology? Kay McCallum Acute Oncology Advanced Nurse Practitioner John Radcliffe Hospital Oxford September 2015

On-going and planned colorectal cancer clinical outcome analyses

Integrated Diabetes Care in Oxfordshire -patient's perspective. Avril Surridge

Carolyn Costigan and Andrea Shemilt Nottingham University Hospitals NHS Trust

GYNAE NSSG LEADS MEETING: Gynaecological Hub

Staging Issues: Lung Cancer & Mesothelioma. Mick Peake Clinical Lead, NCIN Chair, Lung SSCRG

Asthma Audit Development Project: Hospital pilot information

COLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer

An Overview of Health Economics Data and Expertise in Cancer

North Thames Children and Young People s Cancer Network

National Prostate Cancer Audit. Bill Cross June 2015

Routes to diagnosis 2015 update: head and neck salivary gland cancer. National Cancer Intelligence Network Short Report.

The next steps

3. Title Vaccination and immunisation data return collected through the COVER

ADJUVANT CHEMOTHERAPY...

Developing Key Messages on Cancer for Commissioners

National Cancer Patient Experience Programme. 2012/13 National Survey. James Paget University Hospitals NHS Foundation Trust. Published August 2013

WELSH INFORMATION STANDARDS BOARD

for healthcare professionals

National Cancer Patient Experience Programme. 2012/13 National Survey. Milton Keynes Hospital NHS Foundation Trust. Published August 2013

02/GMS/0030 ADULT EPILEPSY SERVICE CCP for General Medical and Surgical POOLE HOSPITAL NHS FOUNDATION TRUST

National Cancer Patient Experience Programme. 2012/13 National Survey. East Kent Hospitals University NHS Foundation Trust. Published August 2013

National Cancer Survivorship Initiative

CNS SSCRG Work Programme

Indicator. title: Indicator ref.: A similar CCG rehabilitation, considerationss for. Denominator. the NICE Committee. The HSCIC is.

eprescribing of Chemotherapy The Leeds Experience Julie Mansell, Lead Chemotherapy Pharmacist, Leeds Cancer Centre

Integrated Impact Assessment Report for Clinical Commissioning Policies

National Lung Cancer Audit outlier policy 2017

CHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY

Consultant-led Referral to Treatment (RTT) waiting times collection timetable: outcome of consultation

Effectiveness of the Get Checked diabetes programme

Routes to diagnosis 2015 update: leukaemia: chronic myeloid. National Cancer Intelligence Network Short Report. Key messages

Transcription:

6.19... to improve the collection and publication of data on chemotherapy activity, outcomes and costs, the chemotherapy dataset will be introduced in April 2012 and this should provide commissioners, providers and others with invaluable information; and to enhance the information available to patients on the benefits and toxicities of treatment

Cancer 10% NHS budget Chemotherapy 100,000,000+ annually Who has what, where, when and why? What does it cost and what are the benefits? NAO report critical Chemotherapy (SACT) dataset National regimen list Payments by results

National implementation group all disciplines Develop a dataset which is rich enough to be useful but small/generic enough to be collectable from all providers for all tumour sites Capable of collecting data on all current and predictable management Robust enough to achieve implementation Not intended to replace audit or research

Each field had to pass: Is it collectable electronically? Is it applicable to most tumour sites? Will the content be consistent? What would you do with it that justifies national collection? Can it linked meaningfully to other datasets?

Includes all drugs given with an anti-cancer affect Cytotoxics Drugs affecting the immune response Hormones and hormone antagonists Bisphosphonates

Solid tumours Haematological malignancy Paediatric tumours Inpatient, daycase, outpatient and community settings Excludes non cancer chemotherapy

Programme Pre-planned sequence of treatment with a purpose Regimen A group of drugs given in a specific way Cycle Repeating elements within a regimen Administration date Note the term course is not used

administration day cycle administration day = bolus injection/ infusion commenced/ oral component commenced chemotherapy programme regimen cycle etc. stop

cycle 1 admin. day admin. day regimen 1 cycle 2 cycle 3 chemotherapy programme cycle 1 regimen 2 cycle 2 cycle 3

cycle 1 admin. day cycle 1 admin. day regimen 1 cycle 2 cycle 2 chemotherapy programme cycle 3 etc regimen 2 cycle 3

A typical protocol tree view of a complex treatment protocol with decison points.

All NHS datasets must go through this process which comprises: Requirement Stage Definitional testing Draft Stage Piloting Full Stage Issue of an ISN to the NHS

National Chemotherapy Implementation Group (NCIG) Chemotherapy Information Group co-ordinates governance, management and maintenance of SACT dataset NCIN Site Specific Clinical Reference Groups (SSCRGs) Commissioning link to Payment by Results (PbR)

The data will flow from e-prescribing and other hospital systems The dataset will be part of the NCIN matrix of interoperable datasets A national chemotherapy regimen list will be common to all chemotherapy collection

The Chemotherapy Intelligence Unit (CIU), has been established which is based at Oxford Data will be sent from trusts on a monthly basis and initial quality checks will be carried out before being incorporated A suite of routine analyses and reporting is being developed and will be issued as soon as feasible

The SACT dataset is divided into six sections: 1. Demographics including commissioner and provider initiating treatment 2. Clinical status 3. Programme and regimen 4. Cycle 5. Drug details 6. Outcome

Current situation Sept 2011 April 2012 April 2012 Sept 2012 Sept 2012 April 2013 April 2013 Sept 2013 Sept 2013 April 2014 From April 2014 onwards Trusts with fully implemented e-prescribing systems Trial downloads (voluntary basis) Start full downloads Continue full downloads Continue full downloads Continue full downloads Continue full downloads Trusts with partially implemented e-prescribing systems Preparation Start partial downloads Start full downloads Continue full downloads Continue full downloads Continue full downloads Electronic clinical system but no e-prescribing Preparation Start partial downloads, dataset sections 1-4 & 6 Continue partial downloads Continue partial downloads Start full downloads Basic hospital systems only Preparation Start partial downloads, dataset sections 1-3 & 6 Continue partial downloads Continue partial downloads Start full downloads

NHS Trusts with fully implemented e-prescribing systems These trusts will be required to submit data in all clinical areas by April 2012. That includes all inpatient, outpatient and community services for all solid tumours, haematological and paediatric malignancy. NHS Trusts with partially implemented e-prescribing systems i.e. not all hospital sites or not all tumour types. These trusts will be required to submit data in all clinical areas that have e- prescribing implemented by April 2012. They will be expected to develop full coverage of all tumour sites and services by September 2012.

Electronic clinical systems but no e-prescribing Systems capable of capturing some information on chemotherapy. These trusts will be required to submit partial data from September 2012. They will be expected to develop the functionality to submit full downloads by April 2014. Basic hospital systems only Systems capable of recording demographics, cancer waiting times and commissioning data. These trusts will be required to submit partial data from September 2012. They will be expected to develop the functionality to submit full downloads by April 2014.

The main data relationships are as follows: Each Patient can have more than one organisation (hospital) during the course of the chemotherapy treatment Each Patient can have one or more diagnoses (tumours) Each Patient can have one or more programmes (generated in the database) Each programme can have one or more regimens Each Regimen will have associated Outcomes Each Regimen can have more than one cycle Each Cycle can have one or more Administration days Each Administration day will have one or more Drug details

Initial feedback on data quality

Based on mandatory fields Overall analyses i.e. based on all data received from all trusts sending monthly returns Regimens commenced by diagnosis group Cycles given by diagnosis and regimen Age spectrum of cycles given by diagnosis Analyses by provider Regimens commenced by diagnosis group Cycles given by diagnosis and regimen

Analysis by intent Analysis by performance status? age banded Regimen summaries reasons for stopping and regimen modification Early deaths following treatment Clinical trial entry

Once returns are being received from all providers, population based analyses are possible and can be linked to incidence and other demographics e.g. Treatment rates per 100,000 population by diagnosis (cycles given or regimens started) Treatment rates by deprivation, ethnicity, etc Treatment completion Early deaths

number of programmes All lung cancer chemotherapy trend by centre 250 200 150 100 50 0

age standardised programmes rate per 100,000 population Lung cancer programmes of chemotherapy 2005/06 25 20 15 10 5 0 ICD-10: C34+45 area of residence

number of programmes 600 Colorectal cancer chemotherapy by regimen by centre 2006-07 500 400 300 200 Other Mitomycin + 5FU Bevacizumab/Cetuximab Capecitabine Oxaliplatin Irinotecan 5FU continuous 5FU DG inc_mod DG 5FU bolus inc_rt 100 0

Questions? How to get your chemotherapy treatment data recording complete and accurate - From MDT systems - From e-prescribing systems?culture change - extended/oral/outliers? national regimen list?what level of aggregation to include in SACT returns? reporting priorities for Haematology (you can only get out what you put in)

1 NHS number M 2 Date of birth M 3 Gender - current R 4 Ethnicity R 5 Patient postcode M 6 GP practice code R 7 Consultant GMC code R 8 Consultant speciality code R 9 Organisation code of provider M M mandatory - record will be rejected without this field R required - must be completed if available and all fields complete by April 2014 O optional - should be completed where relevant to clinical management

10 Primary diagnosis M or field 11 11 Morphology M or field 10 12 Stage of disease R

13 Programme number R 14 Regimen number R 15 Intent of treatment R 16 Regimen M 17 Height at start of regimen R 18 Weight at start of regimen R 19 Performance status at start of regimen R 20 Co-morbidity adjustment R 21 Date decision to treat R 22 Start date of regimen M 23 Clinical trial R 24 Chemo-radiation R 25 Number of cycles planned R

26 Cycle number M 27 Start date of cycle R 28 Weight at start of cycle O 29 Performance status at start of cycle R 30 OPCS procurement code R

31 Drug name R 32 Actual dose per administration R 33 Administration route R 34 Administration date R 35 Organisation code of provider R 36 OPCS delivery code R

37 Date of final treatment R 38 Regimen modification - dose reduction R 39 Regimen modification - time delay R 40 Regimen modification - stopped early R 41 Regimen outcome summary R 42 Date of death R